Jump to content
  • Sign Up
0
Scott Adams

Alvine Pharmaceuticals Presents Results from a Phase 2A Trial of ALV003 in ... - MarketWatch (press release)

Rate this topic

Recommended Posts

Alvine Pharmaceuticals Presents Results from a Phase 2A Trial of ALV003 in ...

MarketWatch (press release)

The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients.

and more »

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×